Industry Webinar
19 Sep 2025

Unlocking the Potential of Antibody-Like Peptide Therapeutics

Discover how our unique CLIPS tricyclic peptide chemistry ensures single-isomer selection early in the screening process, combined with a high-diversity screening method. We showcase the discovery and optimization of tricyclic peptides against high-value targets, like membrane receptor proteins and monoclonal antibodies. Whether you’re in research, biotech, or pharmaceuticals, learn how high-diversity tricyclic peptide screening can support your drug development projects.

Content provided by our supplier

Biosynth Group

  • Country/Region:
    United Kingdom
  • On CPHI since:
    2015
  • Certificates:
    3
  • Employees:
    500 - 999
Company types
Academic/Research
CMO/CDMO
Contract Research Organisation (CRO)
Contract Service
Distributor/Import Export
Manufacturer/Innovator
Primary activities
Chemical Development
Contract Manufacturer
Contract Research Organisation
Custom Manufacturing/Custom Synthesis
Fine Chemicals Company
Intermediates Manufacturer

Other Content from Biosynth Group (30)